Society for Immunotherapy of Cancer (SITC)
Thomas Martin has extensive work experience in various roles within the marketing and communications field. Thomas is currently serving as the Director of Communications and Membership at the Society for Immunotherapy of Cancer (SITC) since July 2021. Prior to this, they worked at the Cancer Treatment Centers of America for 10 years, where they held positions such as Director of Market Development and Manager of Key Market Development. Before that, they worked at FIS as a Senior Marketing Strategy Manager and at Metavante Corp. as the Director of Marketing Services. Thomas began their career at Journal Sentinel Inc. as the E-Marketing and Database Manager, and later served as the Account Services Director.
Thomas Martin attended the Lubar College of Business from 1986 to 1989, where they earned a Bachelor of Science degree. Their field of study focused on Finance/MIS.
Society for Immunotherapy of Cancer (SITC)
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. sitc_log_color.png Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere. Currently, SITC has more than 2,000 members who represent 22 medical specialties in 42 countries around the world. Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.